The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: Exploratory evidence for direct anti-tumour activity in breast cancer

British Journal of Cancer

Volumn 102, Issue 7, 2010, Pages 1099-1105

  Coleman, R E ^a   Winter, M C ^a   Cameron, D ^b   Bell, R ^c   Dodwell, D ^d   Keane, M M ^e   Gil, M ^f   Ritchie, D ^g   Passos Coelho, J L ^h   Wheatley, D ⁱ   Burkinshaw, R ^a   Marshall, S J ^b   Thorpe, H ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Andrew Love Cancer Centre   (Australia)

^d LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL GALWAY   (Ireland)

^f BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

ⁱ ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

Anti tumour activity; Breast cancer; Chemotherapy; Neoadjuvant; Pathological response; ZOL

Indexed keywords

ANTINEOPLASTIC AGENT; ZOLEDRONIC ACID;

ADULT; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; TUMOR VOLUME; UNCONSCIOUSNESS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL;

EID: 77950370156     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605604     Document Type: Article

References (27)

1. Bear HD, Anderson S, Smith RE, Geyer Jr CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N (2006) Sequential preoperative or post-operative docetaxel added to preoperative doxorubicin plus cyclopho-sphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027
2. Buzdar AU (2007) Preoperative chemotherapy treatment of breast cancer-a review. Cancer 110: 2394-2407
3. Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, Klauber-DeMore N, Halle J, Sawyer L, Moore DT, Graham ML (2005) American Joint Committee on Cancer tumor-node-metastasis stage after neoadju-vant chemotherapy and breast cancer outcome. J Natl Cancer Inst 97: 1137-1142
4. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA (2004) Breast conservation after neoadjuvant chemotherapy: the MD Anderson Cancer Center experience. J Clin Oncol 22: 2303-2312 (Pubitemid 41115386) (Pubitemid 41115386)
5. Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 7(Suppl 1): S29-S35
6. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493
7. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685
8. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Post-lberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 360: 679-691
9. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP (2008) Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 26: 814-819
10. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow MH (2002) American Joint Committee on Cancer Staging Manual, 6th edn. Springer-Verlag: New York
11. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O (2002) Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer 3(Suppl 2): S69-S74
12. Jeruss JS, Mittendorf EA, Tucker SL, Gonzalez-Angulo AM, Buchholz TA, Sahin AA, Cormier JN, Buzdar AU, Hortobagyi GN, Hunt KK (2008) Staging of breast cancer in the neoadjuvant setting. Cancer Res 68: 6477-6481
13. Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18: 1927-1934
14. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469
15. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F (2005) Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. Biomed Pharmacother 59(Suppl 2): S387-S392
16. Kurosumi M (2006) Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer. Breast Cancer (Tokyo, Japan) 13: 254-259
17. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74: 1458-1465
18. Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94: 1189-1200
19. NHS Breast Cancer Screening Programme (NHSBSP) and The Royal College of Pathologists (2005) NHSBSP Guidelines for Pathology Reporting in Breast Disease Publication No. 58: 1-134
20. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 126(2): 522-532
21. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100: 1167-1178
22. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Vincent-Salomon A, Vielh P, Bourstyn E (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20: 1304-1310
23. Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G (2006) Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 3: 325-338
24. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25: 4414-4422
25. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in 1 primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237
26. von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa SD, Caputo A, Kaufmann M (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10: R30
27. Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34: 453-475